MOUNTAIN VIEW, Calif., Dec. 19 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. will host a conference call at 8:45 a.m. ET / 5:45 a.m. PT, Friday, December 19, to update shareholders on the worldwide collaboration with AstraZeneca for Unit Dose Budesonide (UDB) announced today.
You may join the call via telephone at 888-670-2248 (domestic) or 913-312- 0980 (international). Access to the live webcast will be available via the Investor Relations section of the Company’s Website at www.mappharma.com. A replay will also be available within 24 hours for at least seven days following the conference call.
About MAP Pharmaceuticals
MAP Pharmaceuticals, Inc. develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals’ pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com
CONTACT: Daryl Messinger, +1-415-999-2361, dmessinger@wcpglobal.com, for
MAP Pharmaceuticals, Inc.
Web site: http://www.mappharma.com//
